Semaglutide Cut Epigenetic Aging by 5 Years in 84 HIV Patients
Updated
Updated · Conexiant · Jun 9
Semaglutide Cut Epigenetic Aging by 5 Years in 84 HIV Patients
3 articles · Updated · Conexiant · Jun 9
Summary
A posthoc analysis of a 32-week randomized trial found semaglutide was tied to markedly lower annualized DNA methylation aging estimates than placebo in HIV patients with lipohypertrophy.
Among 84 participants, the biggest between-group gaps were about 5 fewer epigenetic years for PhenoAge, about 4 for SystemsAge and PCPhenoAge, about 3 for PCGrimAge, plus a 9% slower DunedinPACE aging rate.
Blood-based system clocks also favored semaglutide for inflammation, brain, metabolic, heart, kidney and liver aging estimates, while several first-generation clocks and immune-cell composition measures showed no significant difference.
The findings remain exploratory: epigenetic aging was not a prespecified endpoint, follow-up lasted 32 weeks, the sample was modest, and the study did not test clinical outcomes such as frailty, survival or healthspan.
Researchers said the results suggest GLP-1 drugs may affect biological aging markers in controlled HIV, but prospective trials are needed before treating semaglutide as a gerotherapeutic.
With links to slower aging and lower cancer risk, is this the first true anti-aging drug?
Does this drug directly reverse aging, or is it just a side effect of its metabolic benefits?
Semaglutide Shown to Significantly Slow Epigenetic Aging in Landmark 2026 Clinical Trial
Overview
A landmark study published in May 2026 by Corley et al. provided the first randomized, placebo-controlled clinical evidence that semaglutide, a GLP-1 receptor agonist, can significantly slow epigenetic aging in humans. The trial focused on individuals with HIV-associated lipohypertrophy, but researchers believe the findings have broader implications, as many biological processes in HIV are also fundamental to aging in the general population. Insights from this study mark a significant advancement in aging research and suggest that interventions identified in specific groups could help improve healthspan more widely.